Prognosis: Breakthrough

On this new show from Bloomberg, hosts Mike Regan and Sarah Ponczek speak with expert guests each week about the main themes influencing global markets. They explore everything from stocks to bonds to currencies and commodities, and how each asset class affects trading in the others. Whether you’re a financial professional or just a curious retirement saver, What Goes Up keeps you apprised of the latest buzz on Wall Street and what the wildest movements in markets will mean for your investments. 

Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

On this episode of Prognosis, we'll meet the Bloody Health collective – a group of feminist coders in Berlin who are looking for a safer way to track their periods. Targeted advertising, third-party data sharing and tracking make most menstruation apps just as problematic as they are popular, privacy activists argue. For the women of Bloody Health, the sure way to keep control is to build their own open-source app.

Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

The Pay Check is back for a second season! For the next six weeks, we’re going to dig into the number one reason women still make less money than men: Motherhood. Women start their careers earning just about the same as men do, but once they have their first kid, that pay gap grows to a chasm. This season, we’ll show you how this “motherhood penalty” plays out for real women, in real life and how it affects the global economy.

Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

On the latest edition of Prognosis, we'll tell you how a simple DNA genealogy test upended the life of a Washington state sheep farmer. Instead of finding out more about the Swedish and Jewish roots she'd heard about, she found that she had an entire family she didn't know about, and a connection to a man with a mysterious and controversial past. These types of genetic surprises are getting more common, and redefining who we call family.

Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

Prognosis is back for a second season. Over the next few weeks, we're acknowledging how science and technology are making it easier for us to know pretty much everything there is to know about ourselves: Where we come from. The best time to conceive. What might kill us. And what happens when we start getting all that information, and handing it over to others.

Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

The Pay Check is collecting stories for our upcoming season, and we want to hear from you! Did having a kid change your career trajectory or the way you work? If you have anything you want to share, call and leave us a voicemail at (212) 617-0166. Stay tuned for more very soon!

Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

Some patients can't wait for pharmaceutical companies to develop drugs. They're pushing the drug industry to make the cures they and their loved ones need. But what's good for patients is also good for pharma's profits, creating a web of murky incentives that makes the issue of high drug costs all the more difficult to parse. In episode 8, Bloomberg's Rebecca Spalding talks to these professional patients about their relationships to the big companies whose therapies they need.

Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

Should a patient dying of a disease with no proven cure have the right to try whatever experimental drug they want? A controversial new law signed by President Trump this year says that they should, bypassing the FDA. In episode seven, Bloomberg's Michelle Fay Cortez explores what the new Right To Try law means for desperate patients who want access to experimental treatments. It isn't as simple as it sounds.

Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

When you pick up your prescription at the pharmacy, do you ever wonder how that pill made it your way? Who discovered it? Who believed in it when no one else did? Who invested the money to bring it to market? This week on Prognosis, Bloomberg's Rebecca Spalding tells the surprising journey of one life-saving drug, from discovery to market. It's a story about a Nobel Prize winner, cutting edge genetic research, billions of pharmaceutical dollars, and of all things, a worm. What does it tell us about health care in America?

Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

Researchers and pharmaceutical companies have poured time and money into developing an effective drug to combat obesity. But time and again, the drugs have failed to deliver. In episode five of Prognosis, Bloomberg's James Paton talks to scientists on the cutting edge of weight-loss research, and the companies that may finally be close to finding a medical solution to the obesity crisis.

Learn more about your ad-choices at https://www.iheartpodcastnetwork.com